Evercore ISI analyst Cory Kasimov raised the firm’s price target on Edgewise Therapeutics (EWTX) to $50 from $45 and keeps an Outperform rating on the shares. After the company announced the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy achieved its primary endpoint, the firm notes the 18% “pop” in shares, but believes “there’s ample room” for additional upside in 2025, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics Reports Promising Phase 2 Trial Results
- Edgewise Therapeutics price target raised to $50 from $44 at Leerink
- Morning Movers: Viridian and Edgewise jump following successful trials
- Edgewise reports CANYON Phase 2 trial of sevasemten meets primary endpoint
- Edgewise weakness on FDA warning letter ‘unwarranted,’ says RBC Capital